Clinical Trials
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies
Vaughan, G., Du, R. & Ledley, F.D.
−
July 24, 2024
Institute for New Economic Thinking
Implications of the Inflation Reduction Act for the biotechnology industry; sensitivity of investment and valuation to drug price indices and market conditions
Hyman, C., Dao, H., Vaughan, G. & Ledley, F.
−
July 2024
BMJ Open
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis
Jackson, M.J., Vaughan, G. & Ledley, F.D.
−
March 12, 2024
Institute for New Economic Thinking
Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis
Zhou, E.W., Chaves da Silva, P.G., Quijada, D. & Ledley, F.D.
−
March 2024
PLoS ONE
NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole
Ledley, F.D. & Cleary, E.G.
−
July 26, 2023
JAMA Health Forum
Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
Zhou, E.W., Jackson, M.J. & Ledley, F.D.
−
July 14, 2023
medRxiv
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019
Jackson, M.J., Vaughan, G. & Ledley, F.D.
−
June 4, 2023
JAMA Health Forum
Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019
Galkina Cleary, E., Jackson, M.J., Zhou, E.W. & Ledley, F.D.
−
April 28, 2023
PLoS ONE
Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms
Shah, P., Vaughan, G. & Ledley, F.D.
−
March 31, 2023
Scholars @ Bentley
NIH contribution to phased clinical development of drugs approved from 2010-2019
Zhou, E.W., Jackson, M.J. & Ledley, F.D.
−
February 3, 2023
CIDSA - West Health Policy Center
Will Reducing Drug Prices Slow Innovation?
Vaughan, G. & Ledley, F.D.
−
August 12, 2021
Vaccine
NIH funding for vaccine readiness before the COVID-19 pandemic
Kiszewski, A.E., Cleary, E.G., Jackson, M.J. & Ledley, F.D.
−
March 8, 2021
PLoS ONE
Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016
Cleary, E.G., McNamee, L.M., de Boer, S., Holden, J., Fitzgerald, L. & Ledley, F.D.
−
January 6, 2021
Clinical Therapeutics
Late-Stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016
McNamee, L.M., Cleary, E.G., Zhang, S., Salim, U. & Ledley, F.D.
−
December 27, 2020
Institute for New Economic Thinking
Government as the First Investor in Biopharmaceutical Innovation; Evidence From New Drug Approvals 2010-2019
Cleary, E.G., Jackson, M.J. & Ledley, F.D.
−
September 2020
medRxiv
The role of NIH funding in vaccine readiness; foundational research and NIH funding underlying candidate SARS-CoV-2 vaccines
Kiszewski, A.E., Cleary, E.G., Jackson, M.J. & Ledley, F.D.
−
September 9, 2020
medRxiv
Foundational research and NIH funding enabling Emergency Use Authorization of remdesivir for COVID-19
Cleary, E.G., Jackson, M.J., Folchman-Wagner, Z. & Ledley, F.D.
−
July 6, 2020
The Lancet Oncology
NIH funding for research underlying new cancer therapies
Cleary, E.G. & Ledley, F.D.
−
June 20, 2020
Journal of Microbiology & Biology Education
We Don't Have to Lose STEM Students to Business
Wernick, N.L.B. & Ledley, F.D.
−
April 30, 2020
JAMA
Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies
Ledley, F.D., McCoy, S.S., Vaughan, G. & Cleary, E.G.
−
March 3, 2020
CBE—Life Sciences Education
Representation of Industry in Introductory Biology Textbooks: A Missed Opportunity to Advance STEM Learning
Simon, S.M., Meldrum, H., Ndung'u, E. & Ledley, F.D.
−
November 16, 2018
PNAS
Contribution of NIH funding to new drug approvals 2010–2016
Cleary, E.G, Beierlein, J.M., Khanuja, N.S. & Ledley, F.D.
−
February 12, 2018
Molecular Therapy - Nucleic Acids
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
Beierlein, J.M., McNamee, L.M. & Ledley, F.D.
−
December 15, 2017
Clinical Therapeutics
Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities
Beierlein, J.M., McNamee, L.M., Walsh, M.J., Kaitin, K.I., DiMasi, J.A. & Ledley, F.D.
−
June 24, 2017
PLoS ONE
Timelines of translational science: from technology initiation to FDA approval
McNamee, L.M., Walsh, M.J. & Ledley, F.D.
−
May 8, 2017
PLoS ONE
Modeling timelines for translational science in cancer; the impact of technological maturation
McNamee, L.M. & Ledley, F.D.
−
March 27, 2017
Oceanography
Marine Microalgae: Climate, Energy, and Food Security from the Sea
Greene, C.H., Huntley, M.E. Archibald, I., Gerber, L.N., Sills, D.L., Granados, J., Tester, J.W., Beal, C.M., Walsh, M.J., ... & Corless V.
−
November 7, 2016
Environmental Research Letters
Algal food and fuel coproduction can mitigate greenhouse gas emissions while improving land and water-use efficiency
Walsh, M.J., et al.
−
October 28, 2016
Nature Biotechnology
What does the current biotech stock market value?
McNamee, L.M. & Ledley, F.D.
−
August 7, 2015
Clinical Therapeutics
Patterns of innovation in Alzheimer’s disease drug development: a strategic assessment based on technological maturity
Beierlein, J.M., McNamee, L.M., Walsh, M.J., & Ledley, F.D.
−
August 1, 2015
Council on Undergraduate Research
Connecting business and STEM education through undergraduate research
Bouldin, R.M., Hall, G.J., Oches, E.A., Szymanski, D.W., & Ledley, F.D.
−
Summer 2015
Algal Research
Algal biofuel production for fuels and feed in a 100-ha facility: A comprehensive techno-economic analysis and life cycle assessment
Beal, C.M., Gerber, L.N., Sills, D.L., Huntley, M.E., Machesky, S.C., Walsh, M.J., ... & Greene, C.H.
−
July, 2015
Journal of Microbiology & Biology Education
Positioning Genomics in Biology Education: Content Mapping of Undergraduate Biology Textbooks
Wernick, N.L., Ndung'u, E., Haughton, D. & Ledley, F.D.
−
December 15, 2014
PLoS ONE
Translational Science by Public Biotechnology Companies in the IPO “Class of 2000”: The Impact of Technological Maturity
McNamee, L. & Ledley, F.
−
December 16, 2013
Gene Therapy
Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies
Ledley, F.D., McNamee, L.M., Uzdil, V. & Morgan, I.W.
−
December 5, 2013
Nature Biotechnology
Making the biotech IPO work
McNamee, L.M. & Ledley, F.D.
−
November 1, 2013
Journal of Commercial Biotechnology
Assessing the history and value of Human Genome Sciences
McNamee, L.M. & Ledley, F.D.
−
September 3, 2013
Journal of Management Education
Learning Objectives and Content of Science Curricula for Undergraduate Management Education
Ledley, F.D. & Holt, S.S.
−
November 15, 2012
Nature Biotechnology
Patterns of technological innovation in biotech
McNamee, L.M. & Ledley, F.D.
−
October 10, 2012
The International Journal of Science in Society
Bridging the Boundary between Science and Business
Ledley, F.D.
−
August 13, 2012
Journal of College Science Teaching
Use of Genomic Databases for Inquiry-Based Learning about Influenza, Journal of College Science Teaching
Ledley F.D. & Ndung'u E.
−
March 2011
